Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 34, 221-224, January 1, 1974]
© 1974 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimmerman, T. P.
Right arrow Articles by Elion, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimmerman, T. P.
Right arrow Articles by Elion, G. B.

Identification of 6-Methylmercaptopurine Ribonucleoside 5'-Diphosphate and 5'-Triphosphate as Metabolites of 6-Mercaptopurine in Man

T. P. Zimmerman, L.-C. Chu, C. J. L. Buggé, D. J. Nelson, G. M. Lyon and G. B. Elion

The Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709

Acid-soluble extracts of bone marrow and blood samples from leukemia patients receiving 6-mercaptopurine were analyzed by anion-exchange high-pressure liquid chromatography. This has led to the identification of two previously unrecognized metabolites of 6-mercaptopurine, 6-methylmercaptopurine ribonucleoside 5'-diphosphate and the corresponding 5'-triphosphate. Intracellular concentrations of 6-methylmercaptopurine ribonucleoside 5'-triphosphate often exceeded those of either the corresponding 5'-mono- or 5'-diphosphate and were estimated to be as high as 145 µM. There is no evidence at present that these newly reported metabolites of 6-mercaptopurine are themselves highly cytotoxic, but they may perhaps contribute to the overall cytotoxicity of 6-mercaptopurine.

Received 8/13/73. Accepted 10/19/73.




This article has been cited by other articles:


Home page
BloodHome page
G. Zaza, M. Cheok, W. Yang, J. C. Panetta, C.-H. Pui, M. V. Relling, and W. E. Evans
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment
Blood, September 1, 2005; 106(5): 1778 - 1785.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
T. Dervieux, Y. Chu, Y. Su, C.-H. Pui, W. E. Evans, and M. V. Relling
HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy
Clin. Chem., January 1, 2002; 48(1): 61 - 68.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1974 by the American Association for Cancer Research.